Vaccinex enters 8 ActivMAb agreements including 3 major pharma companies for complex membrane targets

VACCINEX, INC.

Eight new antibody discovery agreements integrate ActivMAb platform, with 3 major pharma/biotech companies and 5 strategic antibody-service partners.
ActivMAb 'Antigen Virus' application targets difficult multi-pass membrane proteins such as GPCRs, ion channels, and chemokine receptors.
Technology enables antibody drug conjugate (ADC) development for cancer; platform uses purified viral presentation for efficient selection.
Agreements signed within last 3 months; CEO cites renewed market optimism after two-year biotech downturn as driver of interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.